February 20, 2025 11:18 AM ESTUpdated 03:37 PM
R&D

In sin­gle case, spinal mus­cu­lar at­ro­phy drug giv­en be­fore birth spared ba­by of ge­net­ic dis­ease symp­toms

Lei Lei Wu

News Reporter

A moth­er took the spinal mus­cu­lar at­ro­phy drug Evrys­di be­fore giv­ing birth to a ba­by with the dev­as­tat­ing ge­net­ic dis­ease. The ba­by, who went on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Marks’ ex­it at FDA rat­tles an al­ready tee­ter­ing biotech in­dus­try

Al­pha­bet’s Iso­mor­phic Labs rais­es $600M in biotech’s largest round of 2025 

FDA's Pe­ter Marks re­signs, says he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Ver­tex’s sec­ond-gen­er­a­tion di­a­betes cell ther­a­py fails ear­ly-stage study

In­spir­na, which was prepar­ing for a Phase 3 can­cer tri­al, has fold­ed

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times